We appreciate Coen Stehouwer and Thomas van Sloten's comments on the clinical relevance of the endpoints in our meta-analysis of individual participant data from the four large trials of more versus less intensive glucose control in patients with type 2 diabetes. The selection of endpoints followed a rigorous, prespecified process that included foremost: consideration of clinical relevance, use of common definitions, standardised ascertainment, and data availability across the trials.
- type 2 diabetes
- Microvascular outcomes
- less intensive glucose control
- selection of endpoints
- composite endpoints